LOUIS BELZIE: Open Payments
NPI 1861438681 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$23,278 in 67 payments from 14 companies in 2025. Trend: 2023 $23,253 · 2024 $45,957 · 2025 $23,278
Speaker / faculty: $12,025Consulting: $7,935Food & beverage: $2,984Travel & lodging: $334
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 14 | $13,348 |
| Janssen Pharmaceuticals, Inc | 15 | $8,130 |
| Alkermes, Inc. | 9 | $421 |
| Neurocrine BioSciences, Inc. | 7 | $374 |
| Otsuka America Pharmaceutical, Inc. | 11 | $225 |
| Luye Pharma (USA) Ltd. | 1 | $130 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Teva Pharmaceuticals USA, Inc. | 1 | $122 |
| Gilead Sciences, Inc. | 1 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $119 |
Products named: INVEGA SUSTENNA, COBENFY, INGREZZA, ARISTADA, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE, SPRAVATO, VOQUEZNA.
Industry payments across NY — which companies pay providers there.
